BRS1-3-7 - Neuronal Membrane DHA Incorporation
(Getting Omega-3 DHA Into Brain Membranes)
1. Mission & Overview
Mission
Deliver and integrate DHA into neuronal membranes so the brain maintains a flexible, signal-ready lipid foundation.
Intervention Dominance: Diet-Dominant
- DHA
No independently established local biochemical cofactors or substrates are specified here. Choline’s upstream carrier relationship is recorded under Key Constraints.
- Methyl-derived DHA-carrier supply
Individual KC inputs
-
Choline
-
Vitamin B9 (folate)
-
Betaine
Overview
DHA, a long-chain omega-3 fat, is built into the phospholipids of neuronal membranes. [3] Membranes that contain it support the structure neurons use to signal. [3] The carrier matters: DHA bound as lysophosphatidylcholine can cross into the brain, and in animals phospholipid DHA accumulated in the brain more than triglyceride DHA. [1] [5] That is structural delivery, not a general omega-3 effect. [3]
- Benefits: DHA in these membranes supports the fluidity and receptor movement that synaptic signalling depends on. [3]
- Implementation Notes: DHA is the provision route. Phospholipid-bound DHA is a delivery form, not a second treatment, and the animal comparison does not set a human dose. [1] [5]
2. Primary Biological Effects
↑ brain DHA accretion; ↑ neuronal membrane DHA enrichment; ↑ membrane fluidity context; ↑ synaptic signalling competence
3. Intervention Levers
Only categories with a substantive evidence-qualified intervention are shown.
No evidence-qualified lifestyle relationship is projected.
4. Mechanistic Basis
Summary
Synaptic signalling depends partly on the lipid composition of neuronal membranes. Phosphatidylcholine can carry DHA; conversion toward lysophosphatidylcholine-DHA (LPC-DHA) presents DHA to the MFSD2A transporter at the blood–brain barrier. Delivery form, not dose slogans, is the mechanistic distinction. This is not an ADHD treatment claim.
(Phosphatidylcholine as DHA and EPA carrier)
Phosphatidylcholine is a principal membrane phospholipid and a dietary carrier for long-chain omega-3 fatty acids. DHA in that phospholipid pool supplies neuronal-membrane architecture and the chemistry that can generate LPC carriers → [Patrick, 2019]
(LPC-DHA and MFSD2A blood–brain barrier transport)
DHA in phosphatidylcholine can be converted to LPC-DHA, which crosses the blood–brain barrier more efficiently than free DHA or triglyceride-bound forms via MFSD2A. That transport step precedes structural incorporation and explains why phospholipid-matrix delivery is distinct from triglyceride-oil dosing → [Patrick, 2019]
(Membrane incorporation and synaptic signalling)
DHA integrates into phospholipid bilayers of neuronal membranes, influencing membrane fluidity, receptor dynamics, and synaptic signalling competence. Incorporation builds over weeks to months of habitual intake rather than through single-meal bolus exposure → [McNamara & Carlson, 2006]
(Phospholipid-bound delivery efficacy)
Phospholipid-bound DHA showed higher gray-matter accretion than triglyceride DHA in neonatal piglets — about 1.9-fold in that comparison. The contrast is animal delivery form, not a human capsule rule and not a choline-intake test → [Liu et al., 2014]
(Boundaries of the mechanism)
This mechanism governs phospholipid-carrier delivery through neuronal-membrane incorporation over habitual intake. Lipid-mediator resolution biology belongs with inflammation-domain mechanisms. Acute amino-acid substrate supply is handled by BRS1-FM1-PM1 - Amino-Acid Availability & Prioritisation. Large-neutral-amino-acid competition at the barrier belongs to BRS1-FM1-PM2 - LAT1 Competitive Transport Modulation. Choline-to-acetylcholine conversion is a different choline fate, represented by BRS1-FM2-PM6 - Acetylcholine Synthesis Support. APOE4-sensitive delivery interpretation is handled by BRS1(SM-SNP2). Membrane PUFA protection and eicosanoid/SPM balance belong downstream with lipid-peroxidation control and eicosanoid–SPM balance.
(Integration within BRS1)
This mechanism operationalises membrane DHA incorporation within BRS1(FM3). Habitual DHA provision and phospholipid/LPC delivery context remain the primary biological levers discussed here.
In 14 healthy adults, intravenous tracer PET and plasma measurements yielded an estimated 3.8 ± 1.7 mg/day of whole-brain DHA incorporation (mean ± SD). This measures replacement from circulating DHA; it is not the amount to eat or take as a supplement Umhau et al. (2009) [8].
Using a previously reported 5 g brain DHA pool, rather than measuring that stock in the participants, the authors estimated 0.076% daily turnover and a 911-day half-life (about 2.5 years). These steady-state estimates do not establish an optimal oral dose, the proportion of a capsule reaching the brain, or clinical benefit. Absorption, peripheral metabolism and delivery form separate swallowed DHA from brain incorporation. In the 14 healthy adults studied, estimated whole-brain DHA incorporation averaged 3.8 ± 1.7 mg/day. Under steady-state assumptions, this represents net replacement of a few milligrams daily: 3.8 − 1.7 = 2.1 mg/day and 3.8 + 1.7 = 5.5 mg/day, or approximately 2–6 mg/day after rounding. This is a descriptive mean ± one standard deviation, not the observed minimum–maximum range, a recommended replacement range or a dietary intake target Umhau et al. (2009) [8].
DHA is one part of brain lipid biology. Human PET also measures incorporation of the omega-6 fatty acid arachidonic acid Giovacchini et al. (2002) [9]. Developing neuronal and glial cultures demonstrate local cholesterol synthesis and uptake Genaro-Mattos et al. (2019) [10]. These are distinct lipid processes, not evidence that additional supplements are required. This PM remains specific to DHA incorporation; the cholesterol culture study does not establish a dietary cholesterol requirement.
4.1 Scientific Findings
Summary
Human PET and plasma measurements estimated whole-brain DHA incorporation at 3.8 ± 1.7 mg/day; turnover and half-life estimates additionally used a previously reported brain DHA pool and steady-state assumptions. [8] A porcine study found greater gray-matter DHA accretion from phospholipid-bound than triglyceride-bound DHA, consistent with reviewed carrier-dependent delivery biology. [5] [1] These findings establish measured incorporation and delivery-form relevance, without defining an optimal oral dose, capsule-to-brain transfer fraction or cognitive benefit.
Docosahexaenoic acid (DHA) is a long-chain omega-3 fat built into neuronal-membrane phospholipids. That is a structural role, not a dosing rule.
What this means
This supports the mission of a signal-ready lipid foundation. It does not show that a single meal resets membranes or that DHA treats ADHD.
Evidence confidence: Not yet scored
Finding ID: PM7-F1
Finding Statement: DHA is a structural polyunsaturated fatty acid of neuronal membranes; that structural role is not a human dosing or ADHD-treatment rule.
Synthesised Evidence Confidence: Not yet scored
Synthesis: A review of omega-3 fats in brain development and function treats DHA as a major structural component of neuronal membranes with implications for signalling architecture. That supports reading this mechanism as membrane composition. It does not measure everyday dietary control of human membrane DHA or isolate ADHD treatment.
Synthesis Limitations: Narrative review spanning development and psychopathology hypotheses. It is not a human membrane-accretion trial after a defined DHA food form.
Evidence Considered:
- Study
- Narrative review of omega-3 roles in brain development, function and psychopathology risk.
- Population
- Mixed developmental, animal and human literature summarised in the review.
- Result
- Identified DHA as a principal membrane PUFA with signalling-architecture implications.
- Effect / Magnitude
- No dietary dose-response or ADHD treatment estimate.
- Evidence Summary
- Establishes the structural membrane role of DHA.
- Limitations
- Review synthesis; not a human incorporation trial.
- Evidence Source
- Inherited repository evidence
- Reference
- [3]
Informs: Focus / Attention Stability; Cognitive Clarity; Emotional Regulation
DHA carried as lysophosphatidylcholine (LPC-DHA) is a preferred substrate for MFSD2A transport at the blood–brain barrier. The phospholipid carrier form matters for presentation.
What this means
Phospholipid-bound DHA is delivery context for this mechanism. It is not a second independent clinical lever and does not by itself prove that choline intake constrains incorporation.
Evidence confidence: Not yet scored
Finding ID: PM7-F2
Finding Statement: LPC-DHA is transported by MFSD2A more efficiently than free or triglyceride-bound DHA; carrier form is a transport property, not a choline-intake or ADHD-dosing rule.
Synthesised Evidence Confidence: Not yet scored
Synthesis: A phosphatidylcholine-DHA review describes conversion toward LPC-DHA and MFSD2A-mediated barrier transport as the efficient route relative to free or triglyceride-bound DHA. That establishes why phospholipid carriage is mechanistically distinct. It does not measure human membrane DHA after ordinary choline intake.
Synthesis Limitations: Mechanistic and disease-context review, including APOE4 discussion. It is not a human dietary-choline or ADHD trial.
Evidence Considered:
- Study
- Review of phosphatidylcholine-DHA transport and APOE4-associated Alzheimer context.
- Population
- Mixed human genetic and mechanistic literature; not a dietary ADHD sample.
- Result
- Identified LPC-DHA / MFSD2A as the efficient barrier-transport route.
- Effect / Magnitude
- No ordinary-diet incorporation estimate.
- Evidence Summary
- Establishes carrier-form transport chemistry.
- Limitations
- Review; does not show choline intake constrains DHA incorporation.
- Evidence Source
- Inherited repository evidence
- Reference
- [1]
Informs: Cognitive Clarity
Dietary DHA provided as phospholipid produced higher gray-matter DHA accretion than the same fatty acid as triglyceride in neonatal piglets. That is an animal delivery-form finding, not a human dosing rule.
What this means
Use this as evidence that phospholipid versus triglyceride form can change accretion in that model. Do not read it as a human capsule dose or an ADHD protocol.
Evidence confidence: Not yet scored
Finding ID: PM7-F3
Finding Statement: Phospholipid-bound dietary DHA produced greater gray-matter DHA accretion than triglyceride-bound DHA in neonatal piglets; that animal contrast is not a human dosing or ADHD-treatment rule.
Synthesised Evidence Confidence: Not yet scored
Synthesis: A controlled porcine comparison found about 1.9-fold greater gray-matter DHA accretion from phospholipid DHA than from triglyceride DHA. That supports a delivery-form difference for accretion. It does not establish human membrane dosing or that choline intake, rather than the DHA phospholipid itself, was the limiting input.
Synthesis Limitations: Neonatal piglets, not children or adults. The contrast is lipid class of DHA, not a choline-supplement arm.
Evidence Considered:
- Study
- Controlled comparison of matched DHA intake as phospholipid versus triglyceride.
- Population
- Neonatal piglets.
- Result
- Approximately 1.9-fold greater gray-matter DHA accretion from the phospholipid form.
- Effect / Magnitude
- About 1.9-fold accretion contrast in that animal model.
- Evidence Summary
- Shows delivery form can change brain DHA accretion in piglets.
- Limitations
- Animal model; not a human dose and not a choline-intake test.
- Evidence Source
- Inherited repository evidence
- Reference
- [5]
Connected / Supportive Evidence:
- Colletti et al. (2021) [6] — MixedWhy relevant: Reviews krill-oil phospholipid omega-3 composition and applications.Why excluded from the primary synthesis: Sourcing and clinical-application review; not a neuronal-membrane incorporation measurement.
- Patted et al. (2024) [7] — MechanisticWhy relevant: Broader omega-3 source and function review, including contaminant-context discussion.Why excluded from the primary synthesis: General source review; not a finding on MFSD2A transport or membrane accretion.
Informs: Cognitive Clarity
A PET study in 14 healthy adults estimated whole-brain DHA incorporation at 3.8 ± 1.7 mg/day. This is brain uptake from circulating unesterified DHA, not a dietary or supplement dose.
What this means
Distinguish measured tracer uptake and plasma DHA from model-derived net incorporation and turnover. These figures do not establish supplement efficacy or an optimal intake.
Evidence confidence: Not yet scored
Finding ID: PM7-F5
Finding Statement: Human PET estimates of circulating DHA incorporation quantify brain replacement under studied conditions; they do not directly measure oral dose requirements.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Umhau et al. combined intravenous [1-11C]DHA PET incorporation coefficients with plasma unesterified DHA concentrations to estimate 3.8 ± 1.7 mg/day (mean ± SD) for the whole brain. Using a previously reported 5 g brain DHA pool, the authors estimated approximately 0.076% daily turnover and a 911-day (about 2.5-year) half-life under a steady-state replacement model.
Synthesis Limitations: The 5 g pool was an external estimate, not measured brain DHA in these participants. Net consumption and half-life are model-derived. The study did not test oral dosing, distinguish all delivery routes, measure supplement benefit, or establish needs during development, deficiency or disease.
Evidence Considered:
- Study
- Intravenous [1-11C]DHA PET kinetic study.
- Population
- 14 healthy adult humans.
- Result
- Measured tracer uptake and plasma DHA were used to calculate whole-brain net incorporation.
- Effect / Magnitude
- 3.8 ± 1.7 mg/day; estimated 911-day half-life using a reported 5 g pool.
- Evidence Summary
- Quantifies adult brain incorporation rather than oral intake.
- Limitations
- Steady-state kinetic model; pool size assumed from prior literature; no oral supplementation comparison.
- Evidence Source
- Bounded external search
- Reference
- [8]
Choline tracing supports contribution to the PEMT-derived LPC-DHA route; separate transport experiments establish LPC-DHA as a brain-delivery substrate.
What this means
Human plasma isotopic enrichment is not absolute hepatic flux, net carrier supply or adult neuronal DHA incorporation. Higher choline intake did not increase total plasma LPC-DHA in the feeding study. The carrier-to-brain connection uses separate cell/mouse transport evidence. Donor inadequacy as a limiting constraint, compensation and benefit from extra intake remain unresolved.
Evidence confidence: Not yet scored
Finding ID: PM7-F6
Finding Statement: Choline tracing supports contribution to the PEMT-derived LPC-DHA route; separate transport experiments establish LPC-DHA as a brain-delivery substrate.
Synthesised Evidence Confidence: Not yet scored
Synthesis: The human controlled-feeding study distinguished methyl-derived d3-LPC-DHA from intact-choline-route d9-LPC-DHA. Higher choline intake increased d3 enrichment without increasing total plasma LPC-DHA. Separate MFSD2A cell assays and labelled uptake in mice establish the transport route. Connecting these studies supports bounded upstream carrier provision, not measured additional adult neuronal incorporation.
Synthesis Limitations: Human plasma isotopic enrichment is not absolute hepatic flux, net carrier supply or adult neuronal DHA incorporation. Higher choline intake did not increase total plasma LPC-DHA in the feeding study. The carrier-to-brain connection uses separate cell/mouse transport evidence. Donor inadequacy as a limiting constraint, compensation and benefit from extra intake remain unresolved.
Evidence Considered:
- Study
- Post hoc isotope analysis of a controlled 10-week choline feeding trial with supplemental DHA.
- Population
- Non-pregnant, pregnant and lactating women; not an adult brain-incorporation experiment.
- Result
- Figures 5–7 distinguish total LPC-DHA from d3 and d9 enrichment; d3 identifies the methyl-derived route.
- Effect / Magnitude
- No main choline effect on total plasma LPC-DHA; increased d3 enrichment. No brain uptake effect estimated.
- Evidence Summary
- Supports choline contribution to the methyl-derived carrier route.
- Limitations
- Full Results and figure captions inspected. Plasma enrichment does not isolate net carrier production or brain delivery; reproductive context affects interpretation.
- Evidence Source
- Bounded external search
- Reference
- [11]
- Study
- Cell transport experiments and Mfsd2a knockout mouse uptake studies.
- Population
- Cells and mice; not choline-fed adult humans.
- Result
- Cell and brain uptake experiments establish the LPC-DHA transport substrate.
- Effect / Magnitude
- Reduced labelled uptake after transporter loss; no dietary methyl-donor effect estimate.
- Evidence Summary
- Supports the carrier-to-brain transport link independently of dietary choline responsiveness.
- Limitations
- Abstract and figure descriptions inspected; full subscription methods/results not obtained. Transporter loss is not donor inadequacy.
- Evidence Source
- Bounded external search
- Reference
- [12]
Folate-dependent remethylation and hepatic betaine/BHMT remethylation replenish methionine for SAM-dependent PEMT chemistry, which connects to the independently established methyl-derived LPC-DHA carrier route.
What this means
Supported biochemical supply chain, not a demonstrated increase in net adult brain DHA incorporation. Folate/choline compensation, hepatic BHMT, SAM turnover and carrier remodelling vary by context. Mouse folate effects were sex/tissue dependent; betaine rescue used ethanol-exposed rats. The downstream human tracer study administered choline, not folate or betaine. A donor-specific limiting effect and extra-intake benefit remain unresolved.
Evidence confidence: Not yet scored
Finding ID: PM7-F7
Finding Statement: Folate-dependent remethylation and hepatic betaine/BHMT remethylation replenish methionine for SAM-dependent PEMT chemistry, which connects to the independently established methyl-derived LPC-DHA carrier route.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Folate-dependent remethylation and hepatic betaine/BHMT remethylation replenish methionine for SAM-dependent PEMT chemistry, which connects to the independently established methyl-derived LPC-DHA carrier route.
Synthesis Limitations: Supported biochemical supply chain, not a demonstrated increase in net adult brain DHA incorporation. Folate/choline compensation, hepatic BHMT, SAM turnover and carrier remodelling vary by context. Mouse folate effects were sex/tissue dependent; betaine rescue used ethanol-exposed rats. The downstream human tracer study administered choline, not folate or betaine. A donor-specific limiting effect and extra-intake benefit remain unresolved.
Evidence Considered:
- Study
- Eight-week folate restriction versus otherwise matched control diets with labelled choline. Indexed primary methods, results and discussion assessed.
- Population
- Male and female Mthfr wild-type and heterozygous mice.
- Result
- Females had lower hepatic d3-PC enrichment and product/precursor enrichment ratio; males lacked that hepatic response.
- Effect / Magnitude
- Hepatic d3-PC enrichment 30% lower (P=0.017); d3-PC:d9-choline ratio P=0.049.
- Evidence Summary
- Donor restriction reduced pathway-specific methyl incorporation in female liver.
- Limitations
- Precursor enrichment, turnover and methyl competition affect this measurement; total PEMT flux was not measured.
- Evidence Source
- Bounded external search
- Reference
- [13]
- Study
- Control/ethanol liquid diets with or without 1% betaine for four weeks. Primary abstract assessed; full assay methods unavailable.
- Population
- Male Wistar rats.
- Result
- Betaine restored SAM:SAH balance and reported PEMT-mediated PC production under ethanol exposure.
- Effect / Magnitude
- No usable numerical production estimate in the abstract.
- Evidence Summary
- Betaine corrected production under an imposed methylation imbalance.
- Limitations
- Supplement rescue does not establish ordinary betaine deficiency; assay details and ethanol context limit attribution.
- Evidence Source
- Bounded external search
- Reference
- [14]
- Froese et al. (2019) [15] — Mechanistic — Establishes folate/B12 remethylation and placement before MAT synthesis; reviewed on PM1-F1.
- Bailey et al. (2021) [16] — Mechanistic — Establishes methionine and ATP use in human MAT2A; reviewed on PM3-F1.
- Evans et al. (2002) [17] — Cellular / Molecular — Human BHMT reaction identity; supports betaine-to-methionine provision, not dietary MAT responsiveness.
- Study
- Post hoc isotope analysis of a controlled 10-week choline feeding trial with supplemental DHA.
- Population
- Non-pregnant, pregnant and lactating women; not an adult brain-incorporation experiment.
- Result
- Figures 5–7 distinguish total LPC-DHA from d3 and d9 enrichment; d3 identifies the methyl-derived route.
- Effect / Magnitude
- No main choline effect on total plasma LPC-DHA; increased d3 enrichment. No brain uptake effect estimated.
- Evidence Summary
- Supports choline contribution to the methyl-derived carrier route.
- Limitations
- Full Results and figure captions inspected. Plasma enrichment does not isolate net carrier production or brain delivery; reproductive context affects interpretation.
- Evidence Source
- Bounded external search
- Reference
- [11]
- Study
- Cell transport experiments and Mfsd2a knockout mouse uptake studies.
- Population
- Cells and mice; not choline-fed adult humans.
- Result
- Cell and brain uptake experiments establish the LPC-DHA transport substrate.
- Effect / Magnitude
- Reduced labelled uptake after transporter loss; no dietary methyl-donor effect estimate.
- Evidence Summary
- Supports the carrier-to-brain transport link independently of dietary choline responsiveness.
- Limitations
- Abstract and figure descriptions inspected; full subscription methods/results not obtained. Transporter loss is not donor inadequacy.
- Evidence Source
- Bounded external search
- Reference
- [12]
Evidence Dependency:
- Reuses klatt_choline_lpc_dha_2019 and nguyen_mfsd2a_transporter_dha_2014 from PM7-F6 for the downstream carrier/transport links; not independent replication. BRS2 PM3-F4 and PM7-F5 sources are reused for specifically assessed upstream links.
5. BRS Pathways and Connections
5.1 BRS Pathways
BRS2-FM1-PM1 — Folate/B12-Dependent Homocysteine Remethylation ↓ BRS2-FM3-PM7 — Phosphatidylcholine Formation ↓ BRS1-FM3-PM7 — Neuronal Membrane DHA Incorporation
5.2 Cross-BRS Mechanism Relationships
Primary Mechanisms in other Biological Regulatory Systems that directly interact with, constrain or support this mechanism.
- BRS3-FM2-PM5 — Lipid Peroxidation Control — Once DHA is in membranes it remains oxidisable; peroxidation control protects those polyunsaturated lipids but is not the incorporation step itself.
- BRS3-FM3-PM8 — Eicosanoid / SPM Balance — Incorporated long-chain fats can feed eicosanoid and specialised pro-resolving mediator chemistry downstream of this membrane job.
5.3 Local BRS Mechanism Relationships
Related Primary Mechanisms within the same Biological Regulatory System that collectively support the integrated biological function.
- BRS1-FM2-PM6 - Acetylcholine Synthesis Support — Converts choline plus acetyl-CoA into acetylcholine. That choline fate is transmitter synthesis, not phosphatidylcholine carriage of DHA for membrane incorporation.
- BRS1-FM1-PM1 - Amino-Acid Availability & Prioritisation — Supplies circulating amino acids for monoamine precursors. Amino-acid pool adequacy is not DHA transport or membrane accretion.
- BRS1-FM1-PM2 - LAT1 Competitive Transport Modulation — Governs competitive brain entry of large neutral amino acids. LAT1 amino-acid competition is not MFSD2A LPC-DHA transport.
7. Phenome Connections
These mappings are translational relationships, not single-mechanism outcome claims. Phenomes are emergent functional patterns supported by multiple interacting PMs across the BRAIN Framework.
Each Phenome relationship has two independent ratings. They are not combined or averaged.
Biology → Phenome Relationship Strength
How direct and important is this biological mechanism expected to be to the Phenome within the BRAIN model?
Evidence Confidence
How strongly does the adjudicated evidence support this particular biology → Phenome relationship?
- Biology → Phenome Relationship Strength: Low–Medium
- Evidence Confidence: Low–Medium
- Rationale: Membrane DHA is a structural context for synaptic signalling McNamara and Carlson (2006) [3]. An observational multi-nutrient study in children seeking help for ADHD-related symptoms cannot isolate membrane DHA from co-supplemented minerals Huss et al. (2010) [2]. Omega-3 ADHD reviews remain contextual Pei-Chen Chang (2021) [4].
Supporting evidence
Children seeking help for ADHD-related symptoms showed attention and emotional-score changes after combined omega-3/6, magnesium and zinc. That observational mix cannot isolate neuronal-membrane DHA.
What this means
Treat Huss as supportive phenome context with hard limits. It is not evidence that membrane DHA incorporation treats ADHD.
Evidence confidence: Not yet scored
Finding ID: PM7-F4
Finding Statement: Observational multi-nutrient supplementation in ADHD-seeking children is translationally adjacent to attention and emotion scores; it cannot isolate membrane DHA incorporation as the cause.
Synthesised Evidence Confidence: Not yet scored
Synthesis: An observational cohort taking omega-3/6 with magnesium and zinc reported SNAP-IV and SDQ changes from baseline. An omega-3 ADHD review supplies personalised-medicine context. Together they keep attention and emotion mappings in view. They do not isolate phospholipid-DHA transport or membrane accretion.
Synthesis Limitations: Uncontrolled observational design and co-supplemented minerals. Chang is a review, not a membrane-DHA trial.
Evidence Considered:
- Study
- Observational cohort of multi-nutrient supplementation.
- Population
- Children seeking medical advice for ADHD-related symptoms.
- Result
- SNAP-IV attention/hyperactivity and SDQ emotional-problem scores improved versus baseline.
- Effect / Magnitude
- Within-cohort score changes; no DHA-only contrast.
- Evidence Summary
- Supplies ADHD-adjacent outcome context with hard attribution limits.
- Limitations
- Observational; omega-3/6 plus magnesium and zinc; not membrane DHA.
- Evidence Source
- Inherited repository evidence
- Reference
- [2]
Connected / Supportive Evidence:
- Pei-Chen Chang (2021) [4] — MechanisticWhy relevant: Reviews omega-3 fatty acids in ADHD as personalised-medicine context.Why excluded from the primary synthesis: Narrative review; does not measure neuronal-membrane DHA incorporation.
- Biology → Phenome Relationship Strength: Low–Medium
- Evidence Confidence: Low–Medium
- Rationale: DHA in neuronal phospholipids supports membrane architecture used in synaptic signalling McNamara and Carlson (2006) [3] Patrick (2019) [1]. Delivery form can change accretion in an animal model Liu et al. (2014) [5]. Those are structural and transport findings, not cognitive-clarity scores after a human DHA change.
- Biology → Phenome Relationship Strength: Medium
- Evidence Confidence: Medium
- Rationale: Combined omega-3/6 with magnesium and zinc was followed by fewer emotional-problem scores in an observational ADHD-seeking cohort Huss et al. (2010) [2]. Membrane DHA remains the mechanism boundary; the multi-nutrient design cannot isolate incorporation McNamara and Carlson (2006) [3].
8. References
- [1] Patrick (2019) — Role of Phosphatidylcholine-DHA in Preventing APOE4-associated Alzheimer's Disease
- [2] Huss et al. (2010) — Supplementation of Polyunsaturated Fatty Acids, Magnesium and Zinc in Children Seeking Medical Advice for ADHD-related Problems
- [3] McNamara and Carlson (2006) — Role of Omega-3 Fatty Acids in Brain Development and Function
- [4] Pei-Chen Chang (2021) — Personalised Medicine Focus on Omega-3 Fatty Acids and ADHD
- [5] Liu et al. (2014) — Higher Efficacy of Dietary DHA Provided as a Phospholipid than as a Triglyceride
- [6] Colletti et al. (2021) — Advances in Technologies for Highly Active Omega-3 Fatty Acids from Krill Oil
- [7] Patted et al. (2024) — Omega-3 Fatty Acids: Sources, Functions and Health Benefits
- [8] Umhau et al. (2009) — Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography
- [9] Giovacchini et al. (2002) — Brain incorporation of carbon-11-labelled arachidonic acid in young healthy humans measured with positron emission tomography
- [10] Genaro-Mattos et al. (2019) — Cholesterol Biosynthesis and Uptake in Developing Neurons
- [11] Klatt et al. (2019) — Choline intake and methyl-derived plasma LPC-DHA
- [12] Nguyen et al. (2014) — MFSD2A transport of LPC-DHA into brain
- [13] Chew et al. (2011) — Upstream Methyl Resource or DHA Carrier Evidence
- [14] Kharbanda et al. (2007) — Upstream Methyl Resource or DHA Carrier Evidence
- [15] Froese et al. (2019) — Upstream Methyl Resource or DHA Carrier Evidence
- [16] Bailey et al. (2021) — Upstream Methyl Resource or DHA Carrier Evidence
- [17] Evans et al. (2002) — Upstream Methyl Resource or DHA Carrier Evidence